Immunotherapy and Hepatocellular Cancer: Where Are We Now?

SIMPLE SUMMARY: HCC is the third-leading cause of cancer death worldwide. Prior to the immunotherapy era, treatment of advanced HCC was dominated by antiangiogenic tyrosine kinase inhibitors, with a quite poor prognosis with a median survival time of around one year. In this review, we aimed to elab...

Descripción completa

Detalles Bibliográficos
Autores principales: Valery, Marine, Cervantes, Baptiste, Samaha, Ramy, Gelli, Maximiliano, Smolenschi, Cristina, Fuerea, Alina, Tselikas, Lambros, Klotz-Prieux, Caroline, Hollebecque, Antoine, Boige, Valérie, Ducreux, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497386/
https://www.ncbi.nlm.nih.gov/pubmed/36139683
http://dx.doi.org/10.3390/cancers14184523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497386/
https://www.ncbi.nlm.nih.gov/pubmed/36139683
http://dx.doi.org/10.3390/cancers14184523

Ejemplares similares